I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Colin Cahill Biography and Net Worth

Director of Shockwave Medical

Colin Cahill serves as Independent Director of the Company. Mr. Cahill has been Vice-President of Venrock since 2012 and focuses on Venrock’s public and cross-over biotech fund. Prior to joining Venrock, Mr. Cahill was a co-founder and Chief Development Officer at Simpirica Spine, Inc. (“Simpirica”), a Bay Area medical device company focused on the development and commercialization of devices for spinal stabilization. Mr. Cahill also served as Simpirica’s Chief Executive Officer from 2006 until 2009. Prior to graduate school, Mr. Cahill worked at the Boston Consulting Group as a strategy consultant. Mr. Cahill received a M.B.A. from the Stanford Graduate School of Business and his M.S. in biological sciences from Stanford University. Mr. Cahill received his B.A. and B.S. in biological sciences and economics, respectively, from Stanford University.

What is Colin Cahill's net worth?: The estimated net worth of Colin Cahill is at least $2.84 million as of May 17th, 2021. Mr. Cahill owns 8,494 shares of Shockwave Medical stock worth more than $2,843,367 as of November 23rd. This net worth evaluation does not reflect any other assets that Mr. Cahill may own. Learn More about Colin Cahill's net worth.
How do I contact Colin Cahill?: The corporate mailing address for Mr. Cahill and other Shockwave Medical executives is 5403 Betsy Ross Drive, Santa Clara CA, 95054. Shockwave Medical can also be reached via phone at (877) 775-4846 and via email at [email protected]. Learn More on Colin Cahill's contact information.
Has Colin Cahill been buying or selling shares of Shockwave Medical?: Colin Cahill has not been actively trading shares of Shockwave Medical during the last ninety days. Most recently, Colin Cahill sold 634 shares of the business's stock in a transaction on Monday, May 17th. The shares were sold at an average price of $157.38, for a transaction totalling $99,778.92. Following the completion of the sale, the director now directly owns 8,494 shares of the company's stock, valued at $1,336,785.72. Learn More on Colin Cahill's trading history.
Who are Shockwave Medical's active insiders?: Shockwave Medical's insider roster includes Colin Cahill (Director), Laura Francis (Director), Douglas Godshall (CEO), Antoine Papiernik (Director), Trinh Phung (VP), Dan Puckett (CFO), Maria Sainz (Director), Frank Watkins (Director), and Isaac Zacharias (Insider). Learn More on Shockwave Medical's active insiders.
Are insiders buying or selling shares of Shockwave Medical?: In the last year, insiders at the sold shares 21 times. They sold a total of 129,216 shares worth more than $30,809,995.81. The most recent insider tranaction occured on March, 26th when Director Laura Francis sold 1,500 shares worth more than $450,000.00. Insiders at Shockwave Medical own 3.4% of the company. Learn More about insider trades at Shockwave Medical.
Information on this page was last updated on 3/26/2024.

Colin Cahill Insider Trading History at Shockwave Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/17/2021	Sell	634	$157.38	$99,778.92	8,494
8/18/2020	Sell	1,832	$55.05	$100,851.60	8,494

Colin Cahill Buying and Selling Activity at Shockwave Medical

Shockwave Medical Company Overview

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Today's Range

Now: $334.75

$334.75

50 Day Range

MA: $332.85

$328.87

$334.83

2 Week Range

Now: $334.75

$157.00

$334.90

Volume

N/A

Average Volume

968,088 shs

Market Capitalization

$12.57 billion

P/E Ratio

78.21

Dividend Yield

N/A

Beta

0.88

I was wrong. Dead wrong.

From Porter & Company | Ad